Ovation Science Inc

PINK:OVATF USA Drug Manufacturers - Specialty & Generic
Market Cap
$1.84 Million
Market Cap Rank
#36085 Global
#11737 in USA
Share Price
$0.05
Change (1 day)
+0.00%
52-Week Range
$0.04 - $0.05
All Time High
$0.48
About

Ovation Science Inc. engages in the production, sub-licensing, and sale of cannabis or hemp products in the United States. The company's patented skin delivery technology Invisicare, a patented polymer-based technology for topical and transdermal skin care products under the Ovation brand name. It also offers cannabis health and wellness solutions under the Invibe MD name; anti-aging products and… Read more

Ovation Science Inc (OVATF) - Net Assets

Latest net assets as of September 2025: $-1.42 Million USD

Based on the latest financial reports, Ovation Science Inc (OVATF) has net assets worth $-1.42 Million USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.80K) and total liabilities ($1.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $-1.42 Million
% of Total Assets -4926.05%
Annual Growth Rate N/A
5-Year Change -135.08%
10-Year Change N/A
Growth Volatility 146.97

Ovation Science Inc - Net Assets Trend (2017–2024)

This chart illustrates how Ovation Science Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Ovation Science Inc (2017–2024)

The table below shows the annual net assets of Ovation Science Inc from 2017 to 2024.

Year Net Assets Change
2024-12-31 $-1.09 Million -67.22%
2023-12-31 $-652.10K -686.12%
2022-12-31 $-82.95K -111.75%
2021-12-31 $706.15K -77.28%
2020-12-31 $3.11 Million +110.36%
2019-12-31 $1.48 Million -32.51%
2018-12-31 $2.19 Million +287.23%
2017-12-31 $565.41K --

Equity Component Analysis

This analysis shows how different components contribute to Ovation Science Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 698639600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $4.52 Million %
Other Comprehensive Income $1.43 Million %
Total Equity $-1.09 Million 100.00%

Ovation Science Inc Competitors by Market Cap

The table below lists competitors of Ovation Science Inc ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Ovation Science Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from -652,104 to -1,090,423, a change of -438,319.
  • Net loss of 456,197 reduced equity.
  • New share issuances of 67,626 increased equity.
  • Other comprehensive income decreased equity by 49,747.
  • Other factors decreased equity by 1.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-456.20K -41.84%
Share Issuances $67.63K +6.2%
Other Comprehensive Income $-49.75K -4.56%
Other Changes $-1.00 -0.0%
Total Change $- %

Book Value vs Market Value Analysis

This analysis compares Ovation Science Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 $0.02 $0.05 x
2018-12-31 $0.14 $0.05 x
2019-12-31 $0.06 $0.05 x
2020-12-31 $0.12 $0.05 x
2021-12-31 $0.02 $0.05 x
2022-12-31 $0.00 $0.05 x
2023-12-31 $-0.02 $0.05 x
2024-12-31 $-0.03 $0.05 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Ovation Science Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -402.95%
  • • Asset Turnover: 1.77x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-58.47%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2017 -10.88% -490.56% 0.01x 1.59x $-118.08K
2018 -23.22% -527.35% 0.04x 1.24x $-727.35K
2019 -56.57% -276.45% 0.16x 1.25x $-983.70K
2020 -38.12% -157.98% 0.23x 1.05x $-1.50 Million
2021 -338.99% -1064.14% 0.29x 1.09x $-2.46 Million
2022 0.00% -574.76% 1.32x 0.00x $-785.76K
2023 0.00% -1312.93% 0.81x 0.00x $-747.94K
2024 0.00% -402.95% 1.77x 0.00x $-347.15K

Industry Comparison

This section compares Ovation Science Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $548,450,613
  • Average return on equity (ROE) among peers: -450.37%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Ovation Science Inc (OVATF) $-1.42 Million -10.88% N/A $991.02K
Ascend Wellness Holdings Inc (AAWH) $142.87 Million -33.75% 5.44x $48.90 Million
AB Science S.A (ABSCF) $10.73 Million -252.65% 3.71x $39.89 Million
Alterola Biotech Inc (ABTI) $4.85K -2005.32% 0.49x $603.58K
Aurora Cannabis Inc (ACB) $2.04 Billion -34.08% 0.34x $199.15 Million
Acreage Holdings Inc (ACRDF) $204.27 Million -30.85% 1.41x $13.48K
Acura Pharmaceuticals Inc (ACUR) $7.90 Million -63.15% 1.15x $13.20K
Agra Ventures Ltd. (AGFAF) $1.51 Million -44.22% 0.06x $298.23K
Allergy Therapeutics plc (AGYTF) $2.07 Million -2084.75% 31.32x $25.30 Million
Aida Pharmaceuticals Inc (AIDA) $6.67 Million 24.51% 2.78x $1.80
Adcock Ingram Holdings Limited (AIHLF) $3.07 Billion 20.55% 0.55x $85.61 Million